Teaching neurologists through microlearning: the first 4 years of the eLearning experience with NeuroBytes (P13-2.001)

Abstract

<h3>Objective:</h3> Determine the impact of the AAN NeuroBytes eLearning program on learning and neurological practice. <h3>Background:</h3> NeuroBytes are brief multimedia videos that provide focused, clinically relevant topic updates in neurology. Neurobytes were launched in January 2019 to deliver microlearning in neurology. We assessed the impact of Neurobytes on satisfaction, learning, and practice. <h3>Design/Methods:</h3> We conducted a programmatic review to evaluate all NeuroBytes from January 2019 (launch) to date of analysis (October 2022). Each NeuroByte course included the video and a survey. Assessment data included: course enrollments, completion rate, satisfaction, and influence on practice. Course enrollment was defined as opening for viewing; course completion required completing the post-course survey which assessed user satisfaction and influence on practice. Data were stratified by user type. To assess the program’s impact, four primary outcomes were defined: (1) course enrollments, (2) course completion rate, (3) satisfaction rate, and (4) percent reporting a change in practice. Descriptive statistics were performed. <h3>Results:</h3> From Jan 2019 – Sept 2022 104 NeuroBytes were released. Total enrollments were 65,089; mean enrollments of 598±377 per course. Mean course completion was 39% (range 7% to 92%). On post-course survey, 87% were satisfied/extremely satisfied. Courses covered 20 subspecialties and COVID-19. The most frequent topics were neuromuscular (n=10) and vascular (n=9). The most popular NeuroByte courses were ‘Dual antiplatelet therapy in ischemic stroke’ (n=1,851 enrollments) and ‘The neurologic exam via telemedicine’ (n=1,848). Member neurologists accounted for 55% of course enrollments, followed by juniors (18%), non-AAN members (13%), APP (6%), or student (3%). <h3>Conclusions:</h3> NeuroBytes are a successful microlearning tool for delivering continuing professional development. The primary strengths of the program are accessibility, high-yield learning, breadth of topics, and appeal to a range of learners. Not all content is conducive to micro-delivery. Ongoing efforts will define how this program influences daily practice and lifelong learning. <b>Disclosure:</b> The institution of Dr. Quick has received research support from NINDS. The institution of Dr. Quick has received research support from NEALS. Dr. Miller has nothing to disclose. Dr. Siegler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. Dr. Siegler has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. Mr. Rook has nothing to disclose. Ms. Morris has nothing to disclose. Mr. Cramer has nothing to disclose. Xiaoyu Sun has received personal compensation for serving as an employee of American Academy of Neurology. An immediate family member of Xiaoyu Sun has received personal compensation for serving as an employee of Syneos Health. An immediate family member of Xiaoyu Sun has stock in Syneos Health. An immediate family member of Xiaoyu Sun has stock in BioNTech. Dr. Cook has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Cook has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Cook has a non-compensated relationship as a Board Member with Alliance for Patient Access that is relevant to AAN interests or activities. Dr. Sabayan has nothing to disclose. The institution of Dr. Kraakevik has received research support from Parkinson Foundation. Dr. Moeller has received publishing royalties from a publication relating to health care. The institution of Dr. Isaacson has received research support from National Institutes of Health. The institution of Dr. Isaacson has received research support from Women’s Alzheimer’s Movement. The institution of Dr. Isaacson has received research support from Aces for Alzheimer’s. Dr. Isaacson has received publishing royalties from a publication relating to health care. Dr. London has nothing to disclose. Dr. Strowd has received personal compensation for serving as an employee of Kaplan. Dr. Strowd has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Monteris Medical, Inc. Dr. Strowd has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Strowd has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Strowd has received research support from Southeastern Brain Tumor Foundation. The institution of Dr. Strowd has received research support from Jazz Pharmaceuticals. The institution of Dr. Strowd has received research support from National Institutes of Health. The institution of Dr. Strowd has received research support from Alpha Omega Alpha. The institution of Dr. Strowd has received research support from American Board of Psychiatry and Neurology. Dr. Strowd has received publishing royalties from a publication relating to health care. Dr. Strowd has received publishing royalties from a publication relating to health care.